Durif F, Vidailhet M, Bonnet A M, Blin J, Agid Y
INSERM U 289, Hôpital de la Salpétrière, Paris, France.
Neurology. 1995 Oct;45(10):1855-8. doi: 10.1212/wnl.45.10.1855.
We evaluated the severity of motor disability and dyskinesias in seven levodopa-responsive patients with Parkinson's disease after an acute challenge with the mixed dopamine agonist, apomorphine, before and after the administration of fluoxetine (20 mg twice per day) for 11 +/- 1 days. After fluoxetine treatment, there was a significant 47% improvement (p < 0.05) of apomorphine-induced dyskinesias without modification of parkinsonian motor disability. The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias (onset- and end-of-dose dyskinesias) and in the upper limbs during choreic mid-dose dyskinesias. The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa- or dopamine agonist-induced dyskinesias without aggravating parkinsonian motor disability.
我们评估了7名左旋多巴反应性帕金森病患者在服用氟西汀(每天2次,每次20毫克)11±1天前后,急性给予混合多巴胺激动剂阿扑吗啡后的运动障碍严重程度和异动症情况。氟西汀治疗后,阿扑吗啡诱发的异动症有显著改善(47%,p<0.05),而帕金森病运动障碍无变化。肌张力障碍性异动症(起始和剂量终末异动症)发作和消失时,异动症主要在下肢减轻;舞蹈样中剂量异动症时,在上肢减轻。结果表明,氟西汀增加脑5-羟色胺能传递,可能减少左旋多巴或多巴胺激动剂诱发的异动症,而不加重帕金森病运动障碍。